Novel drug approvals using expedited programs

STO-REC-STATE42Q7GT1 Official
33

United States · 2024

Novel drug approvals using expedited programs in United States stood at 33 in 2024 (FDA).

Original source
Publisher
FDA
Authority tier
T1 Official
Locator
CDER’s Effectiveness Bringing New Therapies to Market
Retrieved
17 Sep 2026
Status
Verified

What the source says

Expedited Programs: In 2024, CDER approved 33 of the 50 new therapies (66%) using one or more expedited approval programs: fast track designation, breakthrough therapy designation, priority review designation, and Accelerated Approval.

Verbatim extraction verified: The figure 33 is directly attested in the quoted passage (CDER’s Effectiveness Bringing New Therapies to Market).

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA
U.S. Food and Drug Administration. (2024). CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024. Retrieved September 17, 2026, from https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Via StatOrigin, https://statorigin.org/stat/stat_E42Q7GDFNTTE16PB42TN238EC2
MLA
U.S. Food and Drug Administration. "CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024." 2024, https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_E42Q7GDFNTTE16PB42TN238EC2.
Chicago
U.S. Food and Drug Administration. "CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024." 2024. https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_E42Q7GDFNTTE16PB42TN238EC2.
BibTeX
@misc{fda2024novel238ec2, author = {{U.S. Food and Drug Administration}}, title = {CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024}, year = {2024}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_E42Q7GDFNTTE16PB42TN238EC2}, note = {Original source: https://www.fda.gov/news-events/fda-voices/cder-brings-many-safe-and-effective-therapies-patients-and-consumers-2024. Accessed September 17, 2026.} }

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Chain of Custody · Verification Audit
Record: STO-REC-STATE42Q7G T1 Official

Primary Source

Publisher
U.S. Food and Drug Administration · homepage ↗
Authority tier
Tier 1 · Multilateral Official
Report
CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024
Type
Press release
Published
Locator
CDER’s Effectiveness Bringing New Therapies to Market
Retrieved
17 September 2026
Link status
Reachable (HTTP 200)
Report licence
See source

Verification & Integrity

Audit status
Verified
Review protocol
Editorial review
Checked on
17 September 2026
Last revision
17 September 2026
Archival URI
/stat/stat_E42Q7GDFNTTE16PB42TN238EC2